Immunophenotype at diagnosis: distribution of antigen expression intensity in CD371pos and CD371neg BCP-ALL
| Variable . | Screening cohort . | Validation cohort . | P value∗ . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | CD371pos . | CD371neg . | P value . | Total . | CD371pos . | CD371neg . | P value . | ||||||
| n . | n . | % . | n . | % . | n . | n . | % . | n . | % . | ||||
| Total | 843 | 76 | 9.0 | 767 | 91.0 | — | 969 | 84 | 8.7 | 885 | 91.3 | — | .795 |
| CD45 | < .001 | < .001 | |||||||||||
| Strong | 258 | 50 | 65.8 | 208 | 27.2 | 169 | 30 | 85.7 | 139 | 35.0 | .674 | ||
| Weak | 457 | 24 | 31.6 | 433 | 56.6 | 200 | 5 | 14.3 | 195 | 49.1 | .114 | ||
| PP | 2 | 1 | 1.3 | 1 | 0.1 | — | |||||||
| Neg | 124 | 1 | 1.3 | 123 | 16.1 | 63 | 0 | 63 | 15.9 | 1.000 | |||
| Not done | 2 | 0 | 2 | 537 | 49 | 488 | |||||||
| CD19 | .099 | .199 | |||||||||||
| Strong | 819 | 74 | 97.4 | 745 | 97.1 | 963 | 83 | 98.8 | 880 | 99.4 | .757 | ||
| Weak | 23 | 1 | 1.3 | 22 | 2.9 | 4 | 0 | 4 | 0.5 | 1.000 | |||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 0 | 2 | 1 | 1.2 | 1 | 0.1 | |||||||
| CD10 | < .001 | < .001 | |||||||||||
| Strong | 786 | 55 | 72.4 | 731 | 95.3 | 909 | 63 | 75.0 | 846 | 95.5 | .211 | ||
| Weak | 22 | 9 | 11.8 | 13 | 1.7 | 34 | 14 | 16.7 | 20 | 2.3 | .984 | ||
| PP | 13 | 2 | 2.6 | 11 | 1.4 | — | |||||||
| Neg | 22 | 10 | 13.2 | 12 | 1.6 | 26 | 7 | 8.3 | 19 | 2.2 | .186 | ||
| CD58 | .014 | .380 | |||||||||||
| Strong | 749 | 73 | 96.1 | 676 | 88.5 | 687 | 64 | 97.0 | 623 | 98.3 | .077 | ||
| Weak | 82 | 1 | 1.3 | 81 | 10.6 | 12 | 2 | 3.0 | 10 | 1.5 | .042 | ||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 8 | 1 | 1.3 | 7 | 0.9 | 1 | 0 | 1 | 0.2 | 1.000 | |||
| Not done | 3 | 0 | 3 | 270 | 18 | 251 | |||||||
| CD34 | .013 | < .001 | |||||||||||
| Strong | 645 | 68 | 89.5 | 577 | 75.9 | 659 | 78 | 92.9 | 581 | 65.7 | .459 | ||
| Weak | 67 | 0 | 67 | 8.8 | 150 | 4 | 4.8 | 146 | 16.4 | .314 | |||
| PP | 45 | 6 | 7.9 | 39 | 5.1 | — | |||||||
| Neg | 79 | 2 | 2.6 | 77 | 10.1 | 160 | 2 | 2.4 | 158 | 17.9 | .601 | ||
| Not done | 7 | 0 | 7 | — | |||||||||
| CD2 | < .001 | < .001 | |||||||||||
| Strong | 16 | 14 | 18.4 | 2 | 0.3 | 30 | 27 | 32.1 | 3 | 0.3 | 1.000 | ||
| Weak | 17 | 16 | 21.1 | 1 | 0.1 | 84 | 20 | 23.8 | 64 | 7.2 | < .001 | ||
| PP | 8 | 8 | 10.5 | 0 | — | ||||||||
| Neg | 800 | 38 | 50.0 | 762 | 99.6 | 855 | 37 | 44.1 | 818 | 92.4 | .680 | ||
| Not done | 2 | 0 | 2 | — | |||||||||
| CD56 | < .001 | < .001 | |||||||||||
| Strong | 7 | 4 | 5.3 | 3 | 0.4 | 13 | 4 | 4.8 | 9 | 1.0 | .356 | ||
| Weak | 13 | 7 | 9.2 | 6 | 0.8 | 67 | 14 | 16.7 | 53 | 6.0 | .014 | ||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 811 | 64 | 84.2 | 747 | 98.8 | 889 | 66 | 78.5 | 823 | 93.0 | .717 | ||
| Not done | 11 | 0 | 11 | — | |||||||||
| Myeloid antigens† | < .001 | < . 001 | |||||||||||
| Yes | 289 | 42 | 55.3 | 247 | 32.2 | 636 | 70 | 83.3 | 566 | 63.9 | .128 | ||
| No | 554 | 34 | 44.7 | 520 | 67.8 | 333 | 14 | 16.7 | 319 | 36.0 | .218 | ||
| Variable . | Screening cohort . | Validation cohort . | P value∗ . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total . | CD371pos . | CD371neg . | P value . | Total . | CD371pos . | CD371neg . | P value . | ||||||
| n . | n . | % . | n . | % . | n . | n . | % . | n . | % . | ||||
| Total | 843 | 76 | 9.0 | 767 | 91.0 | — | 969 | 84 | 8.7 | 885 | 91.3 | — | .795 |
| CD45 | < .001 | < .001 | |||||||||||
| Strong | 258 | 50 | 65.8 | 208 | 27.2 | 169 | 30 | 85.7 | 139 | 35.0 | .674 | ||
| Weak | 457 | 24 | 31.6 | 433 | 56.6 | 200 | 5 | 14.3 | 195 | 49.1 | .114 | ||
| PP | 2 | 1 | 1.3 | 1 | 0.1 | — | |||||||
| Neg | 124 | 1 | 1.3 | 123 | 16.1 | 63 | 0 | 63 | 15.9 | 1.000 | |||
| Not done | 2 | 0 | 2 | 537 | 49 | 488 | |||||||
| CD19 | .099 | .199 | |||||||||||
| Strong | 819 | 74 | 97.4 | 745 | 97.1 | 963 | 83 | 98.8 | 880 | 99.4 | .757 | ||
| Weak | 23 | 1 | 1.3 | 22 | 2.9 | 4 | 0 | 4 | 0.5 | 1.000 | |||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 0 | 2 | 1 | 1.2 | 1 | 0.1 | |||||||
| CD10 | < .001 | < .001 | |||||||||||
| Strong | 786 | 55 | 72.4 | 731 | 95.3 | 909 | 63 | 75.0 | 846 | 95.5 | .211 | ||
| Weak | 22 | 9 | 11.8 | 13 | 1.7 | 34 | 14 | 16.7 | 20 | 2.3 | .984 | ||
| PP | 13 | 2 | 2.6 | 11 | 1.4 | — | |||||||
| Neg | 22 | 10 | 13.2 | 12 | 1.6 | 26 | 7 | 8.3 | 19 | 2.2 | .186 | ||
| CD58 | .014 | .380 | |||||||||||
| Strong | 749 | 73 | 96.1 | 676 | 88.5 | 687 | 64 | 97.0 | 623 | 98.3 | .077 | ||
| Weak | 82 | 1 | 1.3 | 81 | 10.6 | 12 | 2 | 3.0 | 10 | 1.5 | .042 | ||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 8 | 1 | 1.3 | 7 | 0.9 | 1 | 0 | 1 | 0.2 | 1.000 | |||
| Not done | 3 | 0 | 3 | 270 | 18 | 251 | |||||||
| CD34 | .013 | < .001 | |||||||||||
| Strong | 645 | 68 | 89.5 | 577 | 75.9 | 659 | 78 | 92.9 | 581 | 65.7 | .459 | ||
| Weak | 67 | 0 | 67 | 8.8 | 150 | 4 | 4.8 | 146 | 16.4 | .314 | |||
| PP | 45 | 6 | 7.9 | 39 | 5.1 | — | |||||||
| Neg | 79 | 2 | 2.6 | 77 | 10.1 | 160 | 2 | 2.4 | 158 | 17.9 | .601 | ||
| Not done | 7 | 0 | 7 | — | |||||||||
| CD2 | < .001 | < .001 | |||||||||||
| Strong | 16 | 14 | 18.4 | 2 | 0.3 | 30 | 27 | 32.1 | 3 | 0.3 | 1.000 | ||
| Weak | 17 | 16 | 21.1 | 1 | 0.1 | 84 | 20 | 23.8 | 64 | 7.2 | < .001 | ||
| PP | 8 | 8 | 10.5 | 0 | — | ||||||||
| Neg | 800 | 38 | 50.0 | 762 | 99.6 | 855 | 37 | 44.1 | 818 | 92.4 | .680 | ||
| Not done | 2 | 0 | 2 | — | |||||||||
| CD56 | < .001 | < .001 | |||||||||||
| Strong | 7 | 4 | 5.3 | 3 | 0.4 | 13 | 4 | 4.8 | 9 | 1.0 | .356 | ||
| Weak | 13 | 7 | 9.2 | 6 | 0.8 | 67 | 14 | 16.7 | 53 | 6.0 | .014 | ||
| PP | 1 | 1 | 1.3 | 0 | — | ||||||||
| Neg | 811 | 64 | 84.2 | 747 | 98.8 | 889 | 66 | 78.5 | 823 | 93.0 | .717 | ||
| Not done | 11 | 0 | 11 | — | |||||||||
| Myeloid antigens† | < .001 | < . 001 | |||||||||||
| Yes | 289 | 42 | 55.3 | 247 | 32.2 | 636 | 70 | 83.3 | 566 | 63.9 | .128 | ||
| No | 554 | 34 | 44.7 | 520 | 67.8 | 333 | 14 | 16.7 | 319 | 36.0 | .218 | ||
Bold values correspond to P < .05.
Neg, negative; No, negativity of all myeloid antigens; pos, positive; PP, partial positivity; Strong, strong positivity; Weak, weak positivity; Yes, any positivity (weak, strong, and partial positive).
Comparison of variables distribution between screening (AIEOP) and validation (iBFM-FN) cohorts.
Any myeloid antigen of CD11b, CD14, CD15, CD33, CD64, CD65, MPO, LYSO, CD13, and CD117.